about
Point mutation of the autophosphorylation site or in the nuclear location signal causes protein kinase A RII beta regulatory subunit to lose its ability to revert transformed fibroblastsIndices of methylation in sperm DNA from fertile men differ between distinct geographical regions.Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation.Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis.Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.New perspective for an old antidiabetic drug: metformin as anticancer agent.Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).Modulation of pancreatic cancer chemoresistance by inhibition of TAK1Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.Translational and post-translational modifications of proteins as a new mechanism of action of alpha-interferon: review article.Acetylation of proteins as novel target for antitumor therapy: review article.A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression AnalysisTargeting Raf-kinase: molecular rationales and translational issues.Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trialBiweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor.Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.cAMP-dependent protein kinase: role in normal and malignant growth.Pathophysiologically relevant in vitro tumor models for drug screening.A perspective on the current treatment strategies for locally advanced rectal cancer.Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches.
P50
Q24563837-153F6D5B-EC81-4C85-A810-BA7DBCBA5C3FQ30837026-20041DEF-3BCD-467E-9FE0-C32AC84A2975Q33332446-32182EAB-CC11-406B-B761-06C718CF2DD3Q33367184-E95D04CF-92BD-40B0-A7D1-0E4CD8E13513Q33950156-91F063FA-F017-4D19-B9CC-3896EAAFACF4Q33962243-A214A32D-A198-4381-BC4B-2DDC0585A468Q34101531-F0B5DB14-C3E8-4D49-B43F-87C6E9972EB4Q34238342-F7D89A33-B2FA-4A69-817F-C06744BC4DDAQ34363544-C90C8DB2-2A89-4806-A950-58FFA1747358Q34376878-07387271-3E74-43DB-BF15-266236737606Q34898391-472CDDCC-C64A-4644-8863-1895D64E94BCQ35143975-CF062D0B-93C1-4F9F-A3F9-DAEAEF406C82Q35227104-62F177DE-6767-43E2-B7AD-09AD9323024EQ35854252-4417092D-9054-4898-93E6-73ABCEC287DFQ35854267-FEC77FA9-2030-4BE6-9451-72CFE053EDD8Q35917810-62F9CDE4-BF74-4532-BBA5-9F42EB4643FFQ36031090-D4EAAA58-9BE7-4E00-AC72-BBADC855F64BQ36108999-E85725F7-19CA-4839-8CB4-69ED44FE49D6Q36109003-688B2F19-CC24-4D47-884A-1BA95D225F0CQ36109012-0E7B7089-3861-4F1D-A3A6-8FE791D65F52Q36203560-AC7EA807-FE3E-4E5F-BFB4-ABD4CF086A3DQ36242706-D1773C0B-711A-46CE-B318-09DAC59F98BAQ36499646-F6B52211-AA18-48CF-A9C1-0D599AC6CA27Q36557606-C9727A2F-2A61-4077-8F05-F55DAF23C042Q36614369-E6250810-9E81-46D2-8154-33A2B2BD77C9Q36641041-60DB0276-F033-4B88-9D58-52C49DA7D43FQ36847539-CFA282E7-8F29-47D7-961F-D804943956A6Q36869939-334C2192-B77E-4335-96E7-2DBE3CFAD6E4Q36907149-CCE17F61-9D85-4408-AA84-36CD12DE6338Q36946596-2E774E9F-F715-40A5-83C9-0429F3130FBBQ37066924-3BFD7CBE-E66D-43C6-85B2-782DBB22A5E8Q37066965-A6DBC2F0-D5E5-41B3-AF62-123E1A385DAEQ37066999-C9A341E1-B837-4BA1-8BEB-649853A960BCQ37190106-9ADD1FD7-B165-4446-816D-ACB24CEA8D83Q37577433-12B6A173-BFAB-4BC6-8AF1-F032AFA1CA32Q38149290-70188780-CC9C-429A-AD7D-0507F21DDDBDQ38289628-35AA40A9-47D5-4D60-A8E4-4E3800B4394FQ38440139-27304D1B-BD87-4C3F-AC80-CAB0A0A253F7Q38521351-65C6D76C-6E26-4EAC-B834-C09505EE455BQ38645501-1FBE7B75-00D4-4FC3-9687-6C35E09AAB38
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alfredo Budillon
@ast
Alfredo Budillon
@en
Alfredo Budillon
@es
type
label
Alfredo Budillon
@ast
Alfredo Budillon
@en
Alfredo Budillon
@es
prefLabel
Alfredo Budillon
@ast
Alfredo Budillon
@en
Alfredo Budillon
@es
P106
P1153
7004477157
P21
P31
P496
0000-0002-6330-6053